Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEGHA PATEL-BANKER

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1528229499
CMS profile
159462
Location
ALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,611.18

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,591.49 125
Education $19.69 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEGHA PATEL-BANKER

NPI 1528229499 · CMS profile ID 159462

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

ALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528229499?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEGHA PATEL-BANKER, NPI 1528229499, CMS profile ID 159462. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528229499?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MEGHA PATEL-BANKER, NPI 1528229499, CMS profile ID 159462. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528229499?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MEGHA PATEL-BANKER, NPI 1528229499, CMS profile ID 159462, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1528229499?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $1,611.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $12.9808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813152829 CMS
AbbVie Inc. $17.7908/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559661 CMS
Amgen Inc. $16.1908/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606357 CMS
AbbVie Inc. $24.8008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559655 CMS
PFIZER INC. $4.8108/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833092264 CMS
Janssen Biotech, Inc. $11.8907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788351617 CMS
AstraZeneca Pharmaceuticals LP $14.1007/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829508591 CMS
E.R. Squibb & Sons, L.L.C. $16.4207/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783465521 CMS
Amgen Inc. $15.7207/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606385 CMS
AbbVie Inc. $20.0607/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559649 CMS
AbbVie Inc. $10.5807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559643 CMS
AbbVie Inc. $4.8007/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559637 CMS
AbbVie Inc. $14.4307/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559631 CMS
UCB, Inc. $12.1407/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807372621 CMS
AbbVie Inc. $21.5607/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559625 CMS
Amgen Inc. $17.3407/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606353 CMS
AbbVie Inc. $5.8606/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559619 CMS
GlaxoSmithKline, LLC. $13.0906/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803010781 CMS
AbbVie Inc. $23.6506/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559613 CMS
AbbVie Inc. $16.7606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559603 CMS
Amgen Inc. $11.4906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606381 CMS
E.R. Squibb & Sons, L.L.C. $11.9106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783465509 CMS
Novartis Pharmaceuticals Corporation $16.5706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813152825 CMS
Amgen Inc. $6.1806/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606417 CMS
AbbVie Inc. $5.1606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559597 CMS
Amgen Inc. $5.5706/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606377 CMS
AbbVie Inc. $4.6806/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559591 CMS
AbbVie Inc. $4.3806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559585 CMS
PFIZER INC. $16.2806/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832933643 CMS
E.R. Squibb & Sons, L.L.C. $16.2205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783465503 CMS
GlaxoSmithKline, LLC. $18.4205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802877345 CMS
AbbVie Inc. $18.0905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559579 CMS
AbbVie Inc. $6.2705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559573 CMS
AbbVie Inc. $16.8505/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559567 CMS
Amgen Inc. $17.9505/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606361 CMS
AbbVie Inc. $13.9405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559561 CMS
UCB, Inc. $20.4205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807355889 CMS
AbbVie Inc. $5.8605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559555 CMS
PFIZER INC. $21.3005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832950281 CMS
AbbVie Inc. $11.8005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559549 CMS
AbbVie Inc. $8.8905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559541 CMS
Amgen Inc. $15.2804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825606373 CMS
AbbVie Inc. $18.7304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559535 CMS
GlaxoSmithKline, LLC. $21.1304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802129525 CMS
AbbVie Inc. $3.6304/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559529 CMS
E.R. Squibb & Sons, L.L.C. $4.6004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783465497 CMS
Novartis Pharmaceuticals Corporation $16.5304/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813152821 CMS
AbbVie Inc. $5.0704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559523 CMS
E.R. Squibb & Sons, L.L.C. $15.2004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783465493 CMS
AbbVie Inc. $5.7503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795559517 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,277.20 79
PY2020 $1,802.67 52
PY2021 $1,611.18 126
PY2022 $3,519.90 118
PY2023 $25,366.17 125
PY2024 $40,899.09 155
PY2025 $75,824.25 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $539,537.35 140
PY2024 Principal investigator $514,608.60 154
PY2023 Principal investigator $473,846.55 143
PY2022 Principal investigator $259,736.21 74
PY2021 Principal investigator $140.73 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202535175
Principal investigator 1 ABBVIE INC. $232.00 12/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202535221
Principal investigator 1 ABBVIE INC. $236.60 12/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202535223
Principal investigator 1 Janssen Research & Development, LLC $57.00 12/29/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424678
Principal investigator 1 Janssen Research & Development, LLC $57.00 12/29/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424701
Principal investigator 1 ABBVIE INC. $92.00 12/23/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202531746
Principal investigator 1 ABBVIE INC. $29.07 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202531168
Principal investigator 1 ABBVIE INC. $309.40 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202531170
Principal investigator 1 ABBVIE INC. $22.85 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202531172
Principal investigator 1 ABBVIE INC. $22.85 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531178
Principal investigator 1 ABBVIE INC. $68.85 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202531192
Principal investigator 1 Janssen Research & Development, LLC $598.00 12/18/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424785
Principal investigator 1 ABBVIE INC. $40.73 12/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202530582
Principal investigator 1 ABBVIE INC. $232.00 12/11/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202530016
Principal investigator 1 ABBVIE INC. $236.60 12/11/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202530060
Principal investigator 1 ABBVIE INC. $236.60 12/11/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202530072
Principal investigator 1 Janssen Research & Development, LLC $637.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424567
Principal investigator 1 Janssen Research & Development, LLC $270.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424594
Principal investigator 1 Janssen Research & Development, LLC $126.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424622
Principal investigator 1 Janssen Research & Development, LLC $358.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424636
Principal investigator 1 Janssen Research & Development, LLC $1,049.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424653
Principal investigator 1 Janssen Research & Development, LLC $637.00 12/08/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424696
Principal investigator 1 Janssen Research & Development, LLC $779.00 12/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424659
Principal investigator 1 ABBVIE INC. $2,305.60 12/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527026
Principal investigator 1 ABBVIE INC. $15,007.00 12/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527232
Principal investigator 1 ABBVIE INC. $1,707.80 12/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527234
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,278.97 12/01/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY INSTITUTE, PLLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190311613
Principal investigator 1 ABBVIE INC. $67.50 11/26/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525640
Principal investigator 1 ABBVIE INC. $232.00 11/26/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202525648
Principal investigator 1 PFIZER INC. $5,838.28 11/26/2025 Non-covered Recipient Entity
Megha PatelBanker
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228738402
Principal investigator 1 Janssen Research & Development, LLC $8,318.00 11/24/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424649
Principal investigator 1 ABBVIE INC. $43.20 11/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524950
Principal investigator 1 ABBVIE INC. $11.27 11/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524966
Principal investigator 1 ABBVIE INC. $33.82 11/19/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524664
Principal investigator 1 Janssen Research & Development, LLC $57.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424555
Principal investigator 1 Janssen Research & Development, LLC $500.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424573
Principal investigator 1 Janssen Research & Development, LLC $57.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424642
Principal investigator 1 Janssen Research & Development, LLC $57.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424706
Principal investigator 1 Janssen Research & Development, LLC $57.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424720
Principal investigator 1 Janssen Research & Development, LLC $500.00 11/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424725
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,378.41 11/15/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY INSTITUTE, PLLC
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190311611
Principal investigator 1 ABBVIE INC. $291.00 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202524253
Principal investigator 1 ABBVIE INC. $13.53 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524255
Principal investigator 1 ABBVIE INC. $232.00 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202524271
Principal investigator 1 ABBVIE INC. $74.25 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202524277
Principal investigator 1 Janssen Research & Development, LLC $57.00 11/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424583
Principal investigator 1 ABBVIE INC. $85.00 11/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522883
Principal investigator 1 ABBVIE INC. $74.25 11/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202522885
Principal investigator 1 ABBVIE INC. $27,206.85 11/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520937
Principal investigator 1 ABBVIE INC. $5,737.70 11/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520985
Principal investigator 1 ABBVIE INC. $38.22 11/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521093
Principal investigator 1 Janssen Research & Development, LLC $4,639.00 11/03/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424798
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424577
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424599
Principal investigator 1 Janssen Research & Development, LLC $655.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424684
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424736
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424748
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424765
Principal investigator 1 Janssen Research & Development, LLC $344.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424771
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424777
Principal investigator 1 Janssen Research & Development, LLC $57.00 10/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424781
Principal investigator 1 PFIZER INC. $2,820.58 10/28/2025 Non-covered Recipient Entity
Megha PatelBanker
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228729778
Principal investigator 1 PFIZER INC. $12,038.00 10/25/2025 Non-covered Recipient Entity
Megha PatelBanker
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228741794
Principal investigator 1 ABBVIE INC. $372.60 10/22/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202518169
Principal investigator 1 ABBVIE INC. $232.00 10/21/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202517675
Principal investigator 1 ABBVIE INC. $232.00 10/21/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202517687
Principal investigator 1 ABBVIE INC. $74.25 10/14/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516725
Principal investigator 1 ABBVIE INC. $719.55 10/09/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516185
Principal investigator 1 ABBVIE INC. $12,900.00 10/09/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202516353
Principal investigator 1 PFIZER INC. $9,331.21 10/08/2025 Non-covered Recipient Entity
Megha PatelBanker
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228740454
Principal investigator 1 Janssen Research & Development, LLC $12,364.00 10/06/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424804
Principal investigator 1 PFIZER INC. $233.77 10/06/2025 Non-covered Recipient Entity
DFW Arthritis
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228748539
Principal investigator 1 ABBVIE INC. $232.00 10/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513141
Principal investigator 1 ABBVIE INC. $232.00 09/25/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202512350
Principal investigator 1 PFIZER INC. $230.63 09/09/2025 Non-covered Recipient Entity
Arthritis Rheumatology Research Institute PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228747253
Principal investigator 1 PFIZER INC. $130.00 09/09/2025 Non-covered Recipient Entity
Arthritis Rheumatology Research Institute PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228747771
Principal investigator 1 ABBVIE INC. $232.00 09/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202510176
Principal investigator 1 PFIZER INC. $3,136.00 09/04/2025 Non-covered Recipient Entity
Arthritis Rheumatology Research Institute PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228748432
Principal investigator 1 Janssen Research & Development, LLC $21,493.00 08/28/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424588
Principal investigator 1 ABBVIE INC. $600.00 08/21/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202505483
Principal investigator 1 ABBVIE INC. $232.00 08/12/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202504257
Principal investigator 1 Janssen Research & Development, LLC $9,500.00 08/04/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424755
Principal investigator 1 ABBVIE INC. $232.00 07/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202500726
Principal investigator 1 Janssen Research & Development, LLC $2,858.00 07/31/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175424741
Principal investigator 1 ABBVIE INC. $740.00 07/22/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202499080
Principal investigator 1 ABBVIE INC. $43.20 07/22/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202499112
Principal investigator 1 ABBVIE INC. $373.05 07/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202498422
Principal investigator 1 PFIZER INC. $550.00 07/16/2025 Non-covered Recipient Entity
Megha PatelBanker
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228762825
Principal investigator 1 ABBVIE INC. $232.00 07/15/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202498224
Principal investigator 1 ABBVIE INC. $232.00 07/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495663
Principal investigator 1 ABBVIE INC. $5,597.30 07/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495791
Principal investigator 1 ABBVIE INC. $14,798.85 07/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202495793
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,736.76 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH, PLLC
A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis No dispute reported 06/30/2026 1185541004
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,074.91 07/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH, PLLC
A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis No dispute reported 06/30/2026 1185541006
Principal investigator 1 ABBVIE INC. $232.00 06/17/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202491735
Principal investigator 1 Janssen Research & Development, LLC $161.51 06/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424615
Principal investigator 1 Janssen Research & Development, LLC $54.00 06/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424629
Principal investigator 1 Janssen Research & Development, LLC $161.51 06/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424664
Principal investigator 1 Janssen Research & Development, LLC $363.00 06/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424689
Principal investigator 1 Janssen Research & Development, LLC $1,421.00 06/16/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424730
Principal investigator 1 ABBVIE INC. $59.00 06/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202490363
Principal investigator 1 ABBVIE INC. $5,000.00 06/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202490365
Principal investigator 1 ABBVIE INC. $1,296.05 06/03/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202487877
Principal investigator 1 ABBVIE INC. $31.86 05/29/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202486857
Principal investigator 1 ABBVIE INC. $49.00 05/27/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202486185
Principal investigator 1 ABBVIE INC. $23.74 05/22/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485933
Principal investigator 1 ABBVIE INC. $59.00 05/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485463
Principal investigator 1 ABBVIE INC. $59.00 05/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202485471
Principal investigator 1 ABBVIE INC. $31.05 05/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202485511
Principal investigator 1 ABBVIE INC. $256.50 05/15/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202484995
Principal investigator 1 Janssen Research & Development, LLC $410.00 05/12/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424549
Principal investigator 1 Janssen Research & Development, LLC $71.31 05/12/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424607
Principal investigator 1 Janssen Research & Development, LLC $86.00 05/12/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424672
Principal investigator 1 ABBVIE INC. $5,455.55 05/06/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481405
Principal investigator 1 ABBVIE INC. $7,136.85 05/06/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202482199
Principal investigator 1 Janssen Research & Development, LLC $444.00 05/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424560
Principal investigator 1 Janssen Research & Development, LLC $505.65 05/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424760
Principal investigator 1 ABBVIE INC. $61.43 04/10/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202475954
Principal investigator 1 ABBVIE INC. $61.43 04/10/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202475977
Principal investigator 1 Janssen Research & Development, LLC $235.00 04/07/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424712
Principal investigator 1 Janssen Research & Development, LLC $147.22 04/07/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY RESEARCH INSTITUTE PLLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175424792
Principal investigator 1 ABBVIE INC. $5,753.30 04/03/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473289
Principal investigator 1 ABBVIE INC. $8,525.45 04/03/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202473293
Principal investigator 1 ABBVIE INC. $31.05 04/03/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473297
Principal investigator 1 ABBVIE INC. $31.05 03/20/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202465151
Principal investigator 1 ABBVIE INC. $6,595.50 03/06/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202457567
Principal investigator 1 ABBVIE INC. $2,592.10 03/06/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202457698
Principal investigator 1 ABBVIE INC. $451.00 02/27/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202454484
Principal investigator 1 ABBVIE INC. $142.00 02/27/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202454488
Principal investigator 1 ABBVIE INC. $612.00 02/27/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202454491
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,159.70 02/18/2025 Non-covered Recipient Entity
Arthritis And Rheum Institute PLLC
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235998892
Principal investigator 1 ABBVIE INC. $451.00 02/13/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202451345
Principal investigator 1 ABBVIE INC. $1,707.80 02/05/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202445227
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,263.19 01/21/2025 Non-covered Recipient Entity
Arthritis And Rheumatology Institute, PLLC
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235998882
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $47,330.21 01/17/2025 Non-covered Recipient Entity
Arthritis And Rheumatology Institute, PLLC
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) No dispute reported 06/30/2026 1235998884
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $82,526.78 01/15/2025 Non-covered Recipient Entity
Arthritis And Rheumatology Institute, PLLC
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235998886
Principal investigator 1 UCB SA $320.26 01/14/2025 Non-covered Recipient Entity
ARTHRITIS & RHEUMATOLOGY RSRCH INST
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657020
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $59,747.79 01/13/2025 Non-covered Recipient Entity
Arthritis And Rheumatology Institute, PLLC
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235998888
Principal investigator 1 ABBVIE INC. $341.00 01/09/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202437756
Principal investigator 1 ABBVIE INC. $1,155.65 01/02/2025 Non-covered Recipient Entity
ARTHRITIS AND RHEUMATOLOGY
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202435669